ZeClinics published a study by Patten et al. using zebrafish models to evaluate the efficacy of pimozide for ALS.

ZeClinics is a leading zebrafish-expert CRO, dedicated to tailoring innovative solutions for understanding human disease and advancing drug and target discovery. Our mission is to accelerate research by providing deep in vivo insights, enabling reliable safety and efficacy assessments of new drugs and chemical compounds to reach the market faster. We challenge the traditional discovery process by integrating our expertise in zebrafish biology with cutting-edge lab automation and artificial intelligence. As specialists in CRISPR genome editing, ZeClinics creates custom genome-edited zebrafish models to accurately mimic human diseases. This approach allows us to evaluate the biomedical relevance of candidate compounds and genes in vivo. Our unique zebrafish platforms bridge the gap between cell cultures and mammalian models, offering faster, cost-effective investigations that emphasize proof-of-principle experiments for rapid go/no-go decision making, thereby accelerating the early-stage development of new compounds. ZeClinics offers essential services to pharmaceutical, biotech, nutraceutical, and agrochemical companies, as well as academic research institutions worldwide, helping to enhance and expedite their R&D efforts.

Founded 2013